Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperCOO -0.44%90 Earnings per Share (Diluted) is $1.18 as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 90/100 and a GF Value™ of $101.49 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 660 Medical Devices & Instruments companies, The Cooper ranks better than 52.58% on this metric.
The Cooper's EPS (Basic) for the
three
months ended in Apr. 2026 was $-0.40.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2026 was $1.19.
The Cooper's EPS without NRI for the
three
months ended in Apr. 2026 was $1.21.
Its EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2026 was $4.56.
During the past 12 months, The Cooper's average EPS without NRIGrowth Rate was 17.50% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 10.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 9.10% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 6.80% per year.
During the past 13 years, The Cooper's highest 3-Year average EPS without NRI Growth Rate was 178.70% per year. The lowest was -53.90% per year. And the median was 12.65% per year.
The Cooper (NAS:COO) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
The Cooper Earnings per Share (Diluted) Related Terms
The Cooper Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for The Cooper's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs SOLV, ALGN, BAX: Earnings per Share (Diluted) Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's PE Ratio distribution charts can be found below:
* The bar in red indicates where The Cooper's PE Ratio falls into.
The Cooper Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
The Cooper's Earnings Per Share (Diluted) for the fiscal year that ended in Oct. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $1.18 mean?
The Cooper (COO) has a Earnings per Share (Diluted) of $1.18 as of Apr. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #313 out of 660 companies in the Medical Devices & Instruments industry, placing it in the top 47.4%.
Is The Cooper's Earnings per Share (Diluted) too high?
The Cooper's current Earnings per Share (Diluted) is $1.18. The Medical Devices & Instruments industry median Earnings per Share (Diluted) is 8.15. The Cooper's value of $1.18 is 85.5% below this industry median. Based on the distribution chart, The Cooper ranks #313 out of 660 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Earnings per Share (Diluted) compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #313 out of 660 companies for Earnings per Share (Diluted). This puts The Cooper in the upper half of its industry. The industry median Earnings per Share (Diluted) is 8.15. The Cooper's value of $1.18 is 85.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.15, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Earnings per Share (Diluted) of $1.18 is 85.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Earnings per Share (Diluted) is $1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.49, compared to a current price of $72.31 — trading 28.8% below its estimated fair value. The current Earnings per Share (Diluted) is $1.18 and 85.5% below the Medical Devices & Instruments industry median of 8.15. The Cooper's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For The Cooper (COO), the current Earnings per Share (Diluted) is $1.18 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $72.31 is trading 28.8% below its estimated GF Value™ of $101.49.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
Earnings per Share (Diluted): $1.18
GF Value™: $101.49 vs. price of $72.31 (28.8% below fair value)
Industry Position: 85.5% below the Medical Devices & Instruments median (#313 of 660)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
90GF Score
Get the complete analysis for COO
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
